Summary & Overview
HCPCS Level II J9271: Injection, pembrolizumab, 1 mg
Headline: HCPCS Level II code J9271 — Injection, pembrolizumab, 1 mg — used for reporting pembrolizumab drug units in outpatient settings
Lead: HCPCS Level II code J9271 identifies the 1 mg unit of pembrolizumab, a programmed death receptor-1 (PD-1) immune checkpoint inhibitor widely used across oncology indications. Accurate use of this drug code is essential for consistent billing, clinical documentation, and payer adjudication in outpatient hospital chemotherapy and immunotherapy services.
What the code represents and national relevance: J9271 denotes the drug product of pembrolizumab in 1 mg increments. Nationally, pembrolizumab is a high-cost oncology biologic with multiple labeled and off-label uses; precise unit-level coding supports dose-based billing, inventory tracking, and policy alignment across payers.
Key payers covered: The analysis addresses major commercial payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
What readers will learn: The publication provides benchmarks for how J9271 is billed alongside chemotherapy administration services, typical outpatient hospital use patterns, and payer-specific coverage considerations. It outlines common clinical contexts in which pembrolizumab is administered, clarifies relevant service line relationships, and highlights documentation elements tied to unit-based drug reporting. Where input fields are incomplete, the text notes when specific service-line metadata or proprietary payer policy details are not available.
Note on data availability: Data not available in the input is identified explicitly in the relevant sections of the full publication.
Billing Code Overview
HCPCS Level II code J9271 represents the injection formulation of pembrolizumab dosed at 1 mg per unit. This code is used to report the drug product itself when administered as part of a chemotherapy or immunotherapy regimen.
Service type: Chemotherapy / Immunotherapy drug administration
Typical site of service: Outpatient Hospital (POS 22)
Clinical & Coding Specifications
Clinical Context
A patient diagnosed with a qualifying malignancy, such as metastatic melanoma or non-small cell lung cancer, presents to an outpatient hospital setting (Place of Service 22) for immunotherapy treatment. The oncology team reviews the patient's clinical status and orders pembrolizumab, an immune checkpoint inhibitor, to be administered intravenously. The drug is prepared by pharmacy staff, and the infusion is performed by a trained nurse under physician supervision. The amount of pembrolizumab administered is documented, and any unused drug is recorded for billing purposes. The encounter is coded using J9271 for the drug, with additional codes for the infusion procedure and relevant modifiers as needed.
Coding Specifications
-
Modifiers:
Modifier Code Description Usage JWDrug amount discarded/not administered to any patient Used when a portion of the drug is not administered and must be documented for reimbursement. 59